SUMMIT piques interest
07 December 2018
The SUMMIT study has garnered widespread press attention this week, with chief investigator Professor Sam Janes making several media appearances to raise awareness about what the CTC-coordinated trial is looking to achieve. 

SUMMIT will open in early 2019, delivered by the UCLH Cancer Collaborative in close collaboration with UCL and GRAIL, a US healthcare company focused on the early detection of lung cancer. Prof Janes had the opportunity to extol its virtues on the BBC, Sky News, and ITV.

The study has two aims: to detect lung cancer amongst at-risk Londoners early, when the chance of successful treatment is greatest, and to support the development of a new blood test for the early detection of multiple cancer types, including lung cancer. 

In addition, SUMMIT will provide evidence to inform a potential national lung cancer screening programme. Currently in England, people are offered screening for breast, bowel and cervical cancer, but not lung cancer.

Prof Janes said: 'Lung cancer is the biggest cancer killer in the UK because most people only experience symptoms when the cancer is at an advanced stage when it is very difficult to treat.

'This large-scale study gives us a unique opportunity to detect lung cancer much earlier when treatment is more likely to be successful amongst those proven to be most at risk – people who smoke or used to smoke, aged between 50 and 77.'

Trial coordinator Anne-Marie Mullin remarked: 'This is a really exciting study to be a part of. Seeing the response from the public over the last week has been very encouraging, and we can't wait to start recruiting at the beginning of 2019'.

For more information, visit SUMMIT's website here.
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us